Document:

EX-10.15

 Exhibit 10.15 

PMV PHARMACEUTICALS, INC. 

OUTSIDE DIRECTOR COMPENSATION POLICY 

Adopted and approved by the Board of Directors on August 5, 2020 

PMV Pharmaceuticals, Inc. (the “Company”) believes that providing cash and equity compensation to its members of the
Board of Directors (the “Board,” and members of the Board, the “Directors”) represents an effective tool to attract, retain and reward Directors who are not employees of the Company (the “Outside
Directors”). This Outside Director Compensation Policy (the “Policy”) is intended to formalize the Company’s policy regarding the compensation to its Outside Directors. Unless otherwise defined herein, capitalized
terms used in this Policy will have the meaning given to such terms in the Company’s 2020 Equity Incentive Plan (the “Plan”), or if the Plan is no longer in place, the meaning given to such terms or any similar terms in the
equity plan then in place. Each Outside Director will be solely responsible for any tax obligations incurred by such Outside Director as a result of the equity and cash payments such Outside Director receives under this Policy. 

Subject to Section 8 of this Policy, this Policy will be effective as of the effective date of the first registration statement that is
filed by the Company and declared effective pursuant to Section 12(b) of the Exchange Act, with respect to any class of the Company’s securities (the “Registration Statement”) (such date, the “Effective
Date”). 
  

	 	1.	 CASH COMPENSATION 

Annual Cash Retainer 
 Each Outside
Director will be paid an annual cash retainer of $40,000. There are no per-meeting attendance fees for attending Board meetings. This cash compensation will be paid quarterly in arrears on a prorated basis.

 Committee Annual Cash Retainer 

Effective as of the Effective Date, each Outside Director who serves as the chair of the Board, the lead Outside Director, or the chair or a
member of a committee of the Board listed below will be eligible to earn additional annual cash fees (paid quarterly in arrears on a prorated basis) as follows: 
  

					
	 Chair of the Board
	  	$	35,000	 
	 Chair of Audit Committee:
	  	$	15,000	 
	 Member of Audit Committee:
	  	$	7,500	 
	 Chair of Compensation Committee:
	  	$	10,000	 
	 Member of Compensation Committee:
	  	$	5,000	 
	 Chair of Nominating and Governance Committee:
	  	$	8,000	 
	 Member of Nominating and Governance Committee:
	  	$	4,000	 

 For clarity, each Outside Director who serves as the chair of a committee shall receive only
the additional annual cash fee as the chair of the committee, and not the additional annual cash fee as a member of the committee. 
  

	 	2.	 EQUITY COMPENSATION 

Outside Directors will be eligible to receive all types of Awards (except Incentive Stock Options) under the Plan (or the applicable
equity plan in place at the time of grant), including discretionary Awards not covered under this Policy. All grants of Awards to Outside Directors pursuant to Section 2 of this Policy will be automatic and nondiscretionary, except as
otherwise provided herein, and will be made in accordance with the following provisions: 
 (a)    No Discretion.
No person will have any discretion to select which Outside Directors will be granted any Awards under this Policy or to determine the number of Shares to be covered by such Awards. 

(b)    Initial Award. Each individual who first becomes an Outside Director following the Effective Date will be
granted an award of stock options (an “Initial Award”) covering 172,000 Shares (subject to adjustment for changes in capitalization under the Plan). The Initial Award will be made on the first trading date on or after the date on
which such individual first becomes an Outside Director, whether through election by the stockholders of the Company or appointment by the Board to fill a vacancy. If an individual was a member of the Board and also an employee, becoming an Outside
Director due to termination of employment will not entitle the Outside Director to an Initial Award. 
 Subject to Section 3 of this
Policy, each Initial Award will vest in equal amounts on the same day of the month as the date the individual first becomes an Outside Director over the 36 months following the month during which the individual first becomes an Outside Director,
subject to the Outside Director continuing to be a Service Provider through the applicable vesting date. 

(c)    Annual Award. On the date of each annual meeting of the Company’s stockholders following the Effective
Date (each, an “Annual Meeting”), each Outside Director will be automatically granted an award of stock options (an “Annual Award”) covering 86,000 Shares (subject to adjustment for changes in capitalization under
the Plan). 
 Subject to Section 3 of this Policy, each Annual Award will vest on the earlier of (i) the one-year anniversary of the date the Annual Award is granted or (ii) the day prior to the date of the Annual Meeting next following the date the Annual Award is granted, in each case, subject to the Outside
Director continuing to be a Service Provider through the applicable vesting date. 
  

	 	3.	 CHANGE IN CONTROL

 In the event of a Change in Control, each Outside Director outstanding Company equity awards will accelerate and
vest. 

  
 -2- 

	 	4.	 TRAVEL EXPENSES 

Each Outside Director’s reasonable, customary and documented travel expenses to Board or Board committee meetings will be reimbursed by
the Company. 
  

	 	5.	 ADDITIONAL PROVISIONS 

All provisions of the Plan not inconsistent with this Policy will apply to Awards granted to Outside Directors. 

 

	 	6.	 SECTION 409A 

In no event will cash compensation or expense reimbursement payments under this Policy be paid after the later of (i) 15th day of the 3rd
month following the end of the Company’s fiscal year in which the compensation is earned or expenses are incurred, as applicable, or (ii) 15th day of the 3rd month following the end of the calendar year in which the compensation is earned
or expenses are incurred, as applicable, in compliance with the “short-term deferral” exception under Section 409A of the Internal Revenue Code of 1986, as amended, and the final regulations and guidance thereunder, as may be amended
from time to time (together, “Section 409A”). It is the intent of this Policy that this Policy and all payments hereunder be exempt from or otherwise comply with the requirements of Section 409A so that none
of the compensation to be provided hereunder will be subject to the additional tax imposed under Section 409A, and any ambiguities or ambiguous terms herein will be interpreted to be so exempt or comply. In no event will the Company reimburse
an Outside Director for any taxes imposed or other costs incurred as a result of Section 409A. 
  

	 	7.	 REVISIONS 

The Board may amend, alter, suspend or terminate this Policy at any time and for any reason. No amendment, alteration, suspension or
termination of this Policy will materially impair the rights of an Outside Director with respect to compensation that already has been paid or awarded, unless otherwise mutually agreed between the Outside Director and the Company. Termination of
this Policy will not affect the Board’s or the Compensation Committee’s ability to exercise the powers granted to it under the Plan with respect to Awards granted under the Plan pursuant to this Policy prior to the date of such
termination.         

  
 -3-EX-10.16

 Exhibit 10.16 

PMV PHARMA 

CONSULTING AGREEMENT 

THIS CONSULTING AGREEMENT (the “Agreement”) is made and entered into by and between PMV PHARMA, a Delaware corporation
(the “Company”), and Arnold Levine, Ph.D., an individual (“Consultant”), effective as of January 1, 2016 (“Effective Date”). 

RECITALS 
 WHEREAS,
Consultant has unique skills and knowledge in the Company’s field of endeavor and thus is well suited to advise the Company; and 

WHEREAS, the Company desires that Consultant advise and consult with the Company and Consultant agrees to provide such assistance to
the Company through a consulting relationship with the Company; 
 NOW THEREFORE, in consideration of the mutual obligations
specified in this Agreement, the parties agree to the following: 
  

	1.	 CONSULTING SERVICES ENGAGEMENT. The Company hereby retains Consultant, and Consultant hereby accepts
such retention, to perform consulting services for the Company as set forth herein. 

  

	 	1.1	 SERVICES. Consultant shall provide services described in Exhibit 1 (“Services”) for the
Company. 

  

	 	1.2	 COMPENSATION. Company agrees to pay Consultant the compensation set forth in Exhibit 1.

  

	 	1.3	 TERM AND TIME COMMITMENT. This Agreement will commence on the Effective Date and will continue from the
Effective Date unless terminated earlier by either party according to section 1.6 below. 

  

	 	1.4	 PAYMENT TERMS AND EXPENSE REIMBURSEMENT: 

 

	 	1.4.1	 PAYMENT. Company shall pay Consultant on a monthly basis. 

 

	 	1.4.2	 EXPENSES. The Company shall reimburse Consultant for expenses actually incurred by Consultant in
performing the Services, including but not limited to travel and accommodation expenses, so long as such expenses are reasonable and necessary as determined by the Company and, where such policies exist, comply with the Company’s expense
policies. Consultant shall maintain adequate books and records relating to any expenses to be reimbursed. Consultant shall submit in a timely manner original receipts along with invoices and summarize expenses in a form acceptable to the Company.
Any such expense in excess of $1,500 must be pre-approved by Company before expense is incurred. 

	 	1.5	 INDEPENDENT CONTRACTOR STATUS. It is understood and agreed that Consultant is an independent contractor,
is not an agent or employee of the Company, and is not authorized to act on behalf of the Company. Consultant agrees not to hold himself out as, or give any person any reason to believe that he is an employee, agent, joint venturer or partner of the
Company. Consultant will not be eligible for any employee benefits, nor will the Company make deductions from any amounts payable to Consultant for taxes or insurance. All payroll and employment taxes, insurance, and benefits shall be the sole
responsibility of Consultant. Consultant retains the right to provide services for others during the term of this Agreement and is not required to devote his or her services exclusively for the Company. 

 

	 	1.6	 TERMINATION. The Company or Consultant may terminate this Agreement at any time by giving ten
(10) business days’ written notice. Company may terminate this Agreement immediately upon written notice and without prior notice if Consultant refuses to or is unable to perform the Services or is in breach of any material provision of
this Agreement. In the event of such termination, Consultant shall cease work immediately after receiving such notice of termination, unless otherwise agreed to in writing with the Company. At the time of termination of this Agreement for any
reason, Consultant shall return to the Company all Information, Service Product, and other materials belonging to the Company, and shall notify the Company of any compensation earned and expenses incurred up to the termination date, which
compensation and expenses shall be paid by the Company within 30 days of the Company’s receipt of Consultant’s invoice for same. 

  

	2.	 CONFIDENTIALITY AND ASSIGNMENT OF INVENTIONS. As a condition of this Agreement, Consultant agrees to all
the terms of Section 1, Exhibit 2 (Confidentiality) and Section 2, Exhibit 2 (Assignment of Inventions). 

  

	3.	 SURVIVING SECTIONS. Sections 1 (Confidentiality) and 2 (Ownership of Inventions) of Exhibit 2 of the
Agreement shall survive any termination of this Agreement for the period of five (5) years from the execution of this agreement. 

  

	4.	 ASSIGNMENT; BENEFIT. This Agreement is for the personal services of Consultant and may not be assigned
by him or her, nor shall it be assignable by operation of law, without the prior written consent of the Company. This Agreement may not be assigned by the Company, nor shall it be assignable by operation of law, without the prior written consent of
Consultant. The parties’ rights and obligations under this Agreement will bind and inure to the benefit of their respective successors, heirs, executors, and administrators and permitted assigns. 

 

	5.	 GOVERNING LAW; SEVERABILITY. This Agreement shall be governed by and construed according to the laws of
the State of California without regard to its conflict of laws rules. If any provision of this Agreement is found by a court of competent jurisdiction to be unenforceable, that provision shall be severed and the remainder of this Agreement shall
continue in full force and effect. 

	6.	 COMPLETE UNDERSTANDING; MODIFICATION. This Agreement, together with any Exhibits attached hereto,
constitutes the final, exclusive and complete understanding and agreement of the Company and Consultant with respect to the subject matter hereof. Any waiver, modification or amendment of any provision of this Agreement shall be effective only if in
writing and signed by Consultant and a Company officer. 

  

	7.	 LIABILITY. Consultant represents that he is experienced and qualified to perform the Services hereunder
and shall use his best efforts to provide the Services with the highest level of skill and professionalism. Except for the foregoing, Consultant makes no warranties with regard to the Services and none shall be implied. In no event shall Consultant
be liable for special or consequential damages, either in contract or tort, whether or not the possibility of such damages has been disclosed to Consultant in advance or could have been reasonably foreseen by Consultant. In the event this limitation
of damages is held unenforceable, the parties agree that because of the difficulty in foreseeing possible damages, Consultant’s liability to the Company shall not exceed the amount of any payments made by the Company to Consultant under this
Agreement, any such liability for payment to be construed as liquidated damages and not as a penalty. 

  

	8.	 NOTICES. Any notices required or permitted hereunder shall be given to the appropriate party at the
address specified below or at such other address as the party shall specify in writing. Such notice shall be deemed given upon personal delivery to the appropriate address or sent by certified or registered mail, three days after the date of
mailing. 

  

			
	 If to the Company:
	  	                    If to the Consultant:

 David H. Mack, Ph.D. 

PMV Pharma 
 8 Clark Drive 

Cranbury, NJ 08512 
 [remainder of
page intentionally left blank] 

 IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the
Effective Date. 
  

									
	PMV PHARMA	 		 	NAME OF CONSULTANT
				
	By:	 	 /s/ David H. Mack
	 		 	 /s/ Arnold Levine

		 	David H. Mack, Ph.D.	 		 	Arnold Levine, Ph.D.
			
	 President & CEO
	 		 	 Consultant

	(Title)	 		 	(Title)

									
					
	Date:	 	 1/21/16
	 		 	Date:	 	 1/21/16

 PMV Pharma, Inc. Consulting Agreement 

Exhibit 1 
  

	1.	 SERVICES: Advise and consult with the Company as to such matters as may be mutually agreed by the
Company and Consultant. 

  

	2.	 COMPENSATION: Consultant will be paid $100,000 annually for Services, which will be paid on a monthly
basis. 

  

	3.	 EXPENSES: Consultant shall be reimbursed for reasonable expenses incurred in performance of
Consultant’s obligations; provided these expenses shall be invoiced on a monthly basis and are approved by the Company. Domestic air travel, if approved by the Company, shall be reimbursed at coach or comparable rate; international air travel,
if approved by the Company, shall be reimbursed at business or comparable rate. 

  

	4.	 TIME COMMITMENT: Consultant shall provide consulting services to the Company at Company’s
reasonable request during the term of the Agreement for the term of the agreement or as agreed between Consultant and Company. 

  

	5.	 CONTACT PERSON: David Mack, CEO # 

 PMV Pharma Consulting Agreement 

Exhibit 2 
 Confidentiality and
Assignment of Invention 
  

	1.	 Confidential Information. 

 

	 	1.1	 Subject to the limitations set forth in Paragraph 1.2, all information disclosed by Company to Consultant or
generated by Consultant in the course of performing the Services shall be “Confidential Information.” In particular, Confidential Information shall include, but not be limited to, information relating to any compound, chemical, peptide,
protein, complex, conjugate, assay, biological material, virus, extract, media, vector, gene sequence, cell, cell component, cell line, formulation or sample; any procedure, discovery, invention, formula, data, result, process, idea or technique;
any trade secret, trade dress, copyright, patent or other intellectual property right, or any registration or application therefore, or materials relating thereto; and any information relating to any of the foregoing or to any research, development
(including pre-clinical and clinical development), manufacturing, engineering, marketing, servicing, sales, financing, legal or other business activities or to any present or future products, prices, plans,
forecasts, suppliers, clients, customers, employees, consultants or investors; whether in oral, written, graphic or electronic form. 

  

	 	1.2	 The term “Confidential Information” shall not include information which Consultant can demonstrate by
competent written proof: (a) is now, or hereafter becomes, through no act or failure to act on the part of Consultant, generally known or available in the public domain; (b) is known by Consultant at the time of receiving such information
as evidenced by his/her records or other reasonable proof; or (c) is hereafter furnished to Consultant by a third party, as a matter of right and without restriction on disclosure. 

 

	 	1.3	 Consultant shall maintain all Confidential Information received from Company in trust and confidence and shall
not disclose without the prior written permission of the Company any such Confidential Information to any third party or use any such Confidential Information for any unauthorized purpose. In particular and without limitation, Consultant shall not
use any Confidential Information to support any patent application or related filing. Consultant may use such Confidential Information only to the extent required to perform the Services. Consultant shall not use Confidential Information for any
purpose or in any manner, which would constitute a violation of any laws or regulations, including without limitation the export control laws of the United States. Nothing in this Agreement shall be construed to grant Consultant any rights or
licenses (a) under Company’s trade secrets, trademarks, inventions, copyrights, patents or other intellectual property rights, or (b) to retain, distribute or commercialize any Confidential Information belonging to Company, in either
case, except as necessary to perform the Services. 

	 	1.4	 Other Employer Information. Consultant agrees that he or she will not, during his or her engagement with
the Company, improperly use or disclose any proprietary information or trade secrets of his or her former or concurrent employers, companies or clients, if any, and that he or she will not bring onto the premises of the Company any unpublished
documents or any property belonging to his or her former or concurrent employers, companies or clients unless consented to in writing by said employers, companies or clients. 

 

	 	1.5	 Third Party Information. Consultant recognizes that the Company has received and in the future will
receive from third parties their confidential or proprietary information subject to a duty on the Company’s part to maintain the confidentiality of such information and, in some cases, to use it only for certain limited purposes. Consultant
agrees that he or she owes the Company and such third parties, both during the term of his or her engagement and thereafter, a duty to hold all such confidential or proprietary information in the strictest confidence and not to disclose it to any
person, firm or corporation (except in a manner that is consistent with the Company’s agreement with the third party) or use it for the benefit of anyone other than the Company or such third party (consistent with the Company’s agreement
with the third party). 

  

	2.	 Assignment of Inventions. 

 

	 	2.1	 Disclosure of Inventions. Consultant shall promptly and fully disclose to the Company any and all ideas,
improvements, inventions, know-how, techniques and works of authorship developed by Consultant during his or her performance of the Services for the Company (the “Service Product”). Consultant agrees
to keep and maintain adequate and current records (in the form of notes, sketches, drawings or in any other form that may be required by the Company) of all work performed relating to the Services, including all proprietary information developed
relating thereto, and such records shall be available to and remain the sole property of the Company at all times. 

  

	 	2.2	 Inventions Assigned to the Company. Consultant agrees that any and all Service Product shall be the sole
and exclusive property of the Company. Consultant hereby assigns to the Company all his or her right, title and interest in and to any and all Service Product. Consultant explicitly acknowledges and agrees that all works of authorship contained in
the Service Product are “works for hire” under the copyright laws of the United States, and that the Company shall own the copyright in all such works of authorship. 

Consultant further agrees that the Company is and shall be vested with all rights, title and interests, including patent, copyright, trade
secret and trademark rights, in all of Consultant’s Service Product under this Agreement. 
  

	 	2.3	 Obtaining Intellectual Property Protection. Consultant agrees to assist the Company in every proper way
to obtain and enforce United States and foreign proprietary rights relating to the Service Product in any and all countries. To that end, Consultant agrees to execute, verify and deliver such documents and perform such other acts (including

	 	
appearing as a witness) as the Company may reasonably request for use in applying for, obtaining, perfecting, evidencing, sustaining and enforcing such proprietary rights and the assignment
thereof. In addition, Consultant agrees to execute, verify and deliver assignments of such proprietary rights to the Company or its designee. Consultant’s obligation to assist the Company with respect to proprietary rights in any and all
countries shall continue beyond the termination of his or her engagement, but the Company shall compensate Consultant at a reasonable rate after such termination for the time actually spent by Consultant at the Company’s request on such
assistance. 

 In the event the Company is unable for any reason, after reasonable effort, to secure Consultant’s
signature on any document needed in connection with the actions specified in the preceding paragraph, Consultant hereby irrevocably designates and appoints the Company and its duly authorized officers and agents as his or her agent and attorney in
fact, to act for and in his or her behalf to execute, verify and file, with the same legal force and effect as if executed by him or her, any such documents and to do all other lawfully permitted acts to further the purposes of the preceding
paragraph. Consultant hereby waives and quitclaims to the Company any and all claims of any nature whatsoever which Consultant now or may hereafter have for infringement of any proprietary rights assigned to the Company.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00313-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00313-of-00352.parquet"}]]